TY - BOOK AU - Michael Magdy Farag Abdelmalak AU - Nevine Shawky Abdelmalak , AU - Soad Ali Yehia , TI - A pharmaceutical study on modified drug delivery systems containing a short acting drug / PY - 2017/// CY - Cairo : PB - Michael Magdy Farag Abdelmalak , KW - bi-layered chronopatches KW - Pulsatile release KW - Zaleplon N1 - Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics; Issued also as CD N2 - Zaleplon is a hypnotic drug indicated for the short term management of insomnia for sleep induction. Also it has shown efficacy in treatment of middle of night insomnia without hangover effects. Zaleplon undergoes an extensive hepatic first pass metabolism leaving only 30% systemically available. Its elimination half-life is I hour. ZLP belongs to BCS class II with poor solubility and high permeability. Despite being rapidly absorbed after oral adminstration, the poor aqueous solubility of ZLP limits its dissolution rate and delays its onset of action. The best achieved formula of chaper I FM5 showed optimum mucoadhesion strength (1507.12±62.238 mcg/cm²) and controlled release profile (Q₃hr= 29.06%±0.73% and Q₁₂hr= 87.24%±1.71%) with desirability {u2243} 0.7 UR - http://172.23.153.220/th.pdf ER -